Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
about
Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activityCrystal Structures of Wild-type and Mutant Methicillin-resistant Staphylococcus aureus Dihydrofolate Reductase Reveal an Alternate Conformation of NADPH That May Be Linked to Trimethoprim ResistanceInhibition of Antibiotic-Resistant Staphylococcus aureus by the Broad-Spectrum Dihydrofolate Reductase Inhibitor RAB1Toward New Therapeutics for Skin and Soft Tissue Infections: Propargyl-Linked Antifolates Are Potent Inhibitors of MRSA and Streptococcus pyogenesMethicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyNewer antibacterial drugs for a new century.Postgenomic strategies in antibacterial drug discovery.Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutationsIclaprim.Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Bioactive chemical constituents from the brown alga Homoeostrichus formosana.Current and novel antibiotics against resistant Gram-positive bacteriaInitial efforts toward the optimization of arylomycins for antibiotic activity.New advances in antibiotic development and discovery.Anti-MRSA agents: under investigation, in the exploratory phase and clinically available.Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.Investigational treatments for postoperative surgical site infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Advances in MRSA drug discovery: where are we and where do we need to be?In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.Current challenges in treating MRSA: what are the options?Antimicrobial-resistant Streptococcus pneumoniae: trends and management.Emergence and management of drug-resistant enterococcal infections.Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unitIclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Metalloradical approach to 2H-chromenes.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.Winning the arms race by improving drug discovery against mutating targets.Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges.Significance and biological importance of pyrimidine in the microbial world.Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery.Antibacterial Antifolates: From Development through Resistance to the Next GenerationRecent Advances in the Rational Design and Optimization of Antibacterial Agents.Nickel-catalyzed cross-coupling of chromene acetals and boronic acids.Novel antibiotics for the treatment of Staphylococcus aureus.Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials.Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
P2860
Q27653751-F067996F-7860-4AE7-B1E6-E77FAF689F00Q27653967-7F89F046-083D-4D48-8C0F-5439BD13C8DCQ27663178-22C01E16-B2D2-4FFB-BFCD-A54023E99410Q27677355-855EDA32-49AE-47D6-B483-F3CCE251EB46Q28235095-747C2FC9-6625-4887-9DC0-4ADEAC55A2FAQ30433333-1C8A3556-5412-4E84-A4E9-4D550A0B7A19Q33745572-0EA727A6-2BCF-40E9-8E93-C2D1965CAB6FQ34412978-1B8A5BB1-E5F5-4ABA-9C63-9A6575DB32F9Q34666376-1BC3C378-873B-47FE-AE69-368D4806828AQ34955858-CF227BE3-0367-4DBD-9107-D970E42BBF70Q35016507-F3692703-BDAA-4A93-9BA1-823F7033EF16Q35026521-C2E6FC06-B964-4F5C-9950-D391DE01A03EQ35149887-D25894AE-FE73-4168-9EEA-92E032B0E0B8Q36065983-AF293FB5-5F13-41F2-B048-019792DAF7C0Q36233502-532DD4B9-FB3B-4015-8F27-39F360002CF1Q36548708-9446A1B6-B976-4135-A815-303FC30774F3Q36715742-5E85FBC9-AEC2-4AE6-ADB1-55809D06712AQ36718474-E64B03DA-038E-4469-A58D-7CFBA05FD6E4Q37112508-B1A81CD1-2BA0-43FE-AC60-7F2DF44CD74AQ37144800-069F2D0D-4C0A-4987-9B69-6F47641891B0Q37291338-A62323F9-8342-47FF-9BDE-3A369BDB0AA4Q37291341-4AF7D76D-EF90-4E8C-9340-09948C612B80Q37291346-08D48E12-2F63-49D6-89D6-7D98F4688FD4Q37333096-01D1E6F5-1AD7-43D7-947E-33627565BF28Q37443022-FAA8BBF6-0420-4797-A64C-5D52F795A650Q37478826-0A78423C-3855-4CEA-B0BD-6A766CDB71CCQ37593094-795C742A-7AB0-4FF6-AAA0-FCF55E869D63Q37605771-2608F414-45C6-4B2E-A83A-2C8D31E6BF73Q37785546-3DF5C593-A749-4F46-9A26-782C6299331BQ37924980-9BC8F16A-05B5-432D-98A9-ED1C34C370F1Q37952291-EC75CD41-A87E-4BCB-9A05-7C74FA665926Q38026606-35BF3DCB-97C3-4293-9524-285FD83D62A9Q38266477-92EA20E3-6738-45F9-9C60-FFE5E17752D1Q38792855-D9507FFE-942A-4EB4-90A6-66D7BCBD40CDQ38879756-4D9122CF-EDF0-4981-BA28-8E50D4593BC0Q38958278-97BF65F6-ADD5-4333-AC90-743989CE1641Q39383053-71B4B4AB-5A9C-4452-B40B-A64DB8BA8AF2Q39933945-63A07D53-A278-4BE0-9F45-5885F0599A54Q41835213-80A119FD-A203-4716-91AF-6028DED62944Q42274161-BC8C9205-C682-4E5A-A36E-0BBAE52A424E
P2860
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@ast
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@en
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@nl
type
label
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@ast
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@en
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@nl
prefLabel
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@ast
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@en
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@nl
P2093
P1476
Iclaprim, a novel diaminopyrim ...... sitive and resistant bacteria.
@en
P2093
Khalid Islam
Peter Schneider
Stephen Hawser
P304
P356
10.1016/J.BMCL.2003.07.023
P407
P577
2003-12-01T00:00:00Z